A nurse-led program to support patients with triple-negative breast cancer during their recovery phase
Official title: A Nurse-Led, Coping and Supportive Care Intervention to Improve Psychosocial Outcomes of Patients with Triple-Negative Breast Cancer During the Transition from Curative Therapy to Surveillance
Funded at Massachusetts General Hospital · NIH-10985192 · Data updated 2026-11-12
This study is testing a new support program called TRANSITIONS to help people with triple-negative breast cancer feel better emotionally as they finish their treatment and start regular check-ups, making sure it meets their needs and is helpful for them.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts General Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | July 17, 2024 |
| Project end | June 30, 2029 |
| Funding year | 2024 |
| Award (this year) | $251,519 |
| NIH project number | 1K08CA286755-01A1 |
| Project ID | NIH-10985192 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with triple-negative breast cancer who are transitioning from curative therapy to surveillance.
✕Less likely to help
Patients with other types of breast cancer or those who are not in the transition phase may not benefit from this research.
What this research studies
This research focuses on developing a nurse-led intervention called TRANSITIONS to support patients with triple-negative breast cancer (TNBC) as they move from curative treatment to regular surveillance. The program aims to address the emotional and psychological challenges faced by these patients, particularly during a time of increased anxiety about cancer recurrence. By gathering feedback from patients and stakeholders, the intervention will be refined and tested for its effectiveness in improving psychosocial outcomes. The study will involve a pilot randomized controlled trial to evaluate how well the program works and how acceptable it is to patients.
Why it matters
Potential benefit: If successful, this research could significantly improve the mental health and quality of life for patients transitioning from cancer treatment to surveillance.
How similar studies have gone: Previous research has shown that supportive care interventions can improve psychosocial outcomes for cancer patients, suggesting that this approach may be effective for TNBC patients as well.
Where this research is happening
-
Massachusetts General Hospital
Boston, United States Active
Researchers
- Principal investigator: Post, Kathryn Elizabeth — Massachusetts General Hospital
- Study coordinator: Post, Kathryn Elizabeth
Related research
Other NIH-funded projects on the same topics.
-
Genomic study to understand how genetics and epigenetics shape triple-negative breast cancer in African ancestry
This study looks at how inherited genes and gene activity affect triple-negative breast cancer in people of African ancestry to better understand why outcomes can be worse.
-
Co-Targeting IL-6 and CDK4/6 to Prevent TNBC in Women Veterans
A study aims to block two cancer-promoting pathways (IL-6 and CDK4/6) to prevent or reduce progression of triple-negative breast cancer in women veterans.
-
Linking heavy metal exposure to a tougher breast cancer type (TNBC)
Aimed at understanding how heavy metals like cadmium might trigger a dangerous breast cancer type (TNBC) in people, especially those with BRCA1 risk, to identify possible future treatment strategies.
-
Dormancy in Triple-Negative Breast Cancer: How Liver and Skin Metastases Go Quiet or Reactivate
Researchers will study how dormant cancer cells in liver and skin metastases of triple-negative breast cancer become quiescent or wake up, using organ-on-chip models and single-cell analysis to map chromatin states.
-
Rac-enhanced CAR-Macrophages against TNBC
A new cell therapy approach uses engineered macrophages with a CAR and Rac2 activation to target and kill triple-negative breast cancer cells expressing CSPG4.
-
A new peptide therapy to help treat metastatic triple-negative breast cancer
A new peptide therapy called PEG-FUD is being tested to help treat metastatic triple-negative breast cancer by normalizing the tumor environment to improve treatment delivery.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.